Telix Pharmaceuticals (ASX:TLX) completed the acquisition of therapeutic and diagnostic radiopharmaceutical assets targeting fibroblast activation protein, a pan-cancer target, according to a Wednesday filing with the Australian bourse.
The assets, developed by Professor Frank Roschand and his collaborators at a German University, feature a novel structure that enhances tumor retention and reduces off-target effects, the filing said.
The biopharmaceutical company has paid 5.3 million euros upfront, with an additional 4 million euros due over the next 12 months, subject to certain conditions.
The company will also pay up to 132 million euros in milestone payments tied to clinical and regulatory achievements, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.